The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study

Table 4 Characteristics of 18,485 patients with rheumatoid arthritis at study entry unless otherwise specified

Variable	Patient Data			Community Norms
	Mean (SD)	IQR	Range	Mean (SD)	Range
HAQ	1.06 (0.73)	1.00 (0.50 to 1.62)	0.00 to 3.00
PCS	35.8 (11.0)	34.7 (27.3 to 44.1)	6.5 to 69.4	46.2 (3.4)	40.2 to 55.3
MCS	49.0 (11.3)	51.4 (40.7 to 58.0)	7.6 to 75.2	50.8 (1.46)	45.0 to 52.7
EQ-5D	0.73 (0.19)	0.78 (0.69 to 0.83)	-0.11 to 1.00	0.83 (0.03)	0.79 to 0.93
Age (years)	59.9 (13.0)
Sex (% male)	23.3
Non-Hispanic White (%)	89.8
High school graduate (%)	89.4
College graduate (%)	26.3
Income (median $US)	35,000
RA duration (median IQR) years	9.7 (4.4 to 18.1)
Study duration (years)	3.7 (3.2)		0.5 to 11.0
Study duration biologic comparison) (years)	6.1 (3.0)		1.0 to 11.0
Comorbid conditions (none) (%)	27.2
Comorbid conditions (1) (%)	27.1
Comorbid conditions (≥ 2) (%)	45.8
Satisfied or very satisfied with health (%)	51.5
MTX (%)	47.8
MTX (anytime in study) (%)	60.8
Prednisone (%)	40.5
Biologic (anytime in study) (%)	44.5
DMARD use (lifetime) (%)	92.3
Triple therapy (lifetime) (%)	3.7

HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary; RA, rheumatoid arthritis; MTX, methotrexate; DMARD, Disease-Modifying Anti-Rheumatic Drug; triple therapy, methotrexate (MTX) + hydroxychloroquine (HCQ) + sulfasalazine (SSZ).
Community norms are age and sex-adjusted to the NDB study population.

ISSN: 1478-6362